COMMUNIQUÉS West-GlobeNewswire

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
25/01/2024
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for which Dupixent is [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
25/01/2024
Company Announcement COPENHAGEN, Denmark; January 25, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,281 restricted stock units and 5,468 warrants to employees of the Company and the [...]
Confluent Announces Significant Investment in ATI Nitinol Melt Expansion
25/01/2024
Confluent Becomes ATI’s Fulfillment Partner for Medical Nitinol SCOTTSDALE, Ariz., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to invest more [...]
Renovaro Biosciences Announces Results of Special Meeting of Shareholders
25/01/2024
LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’ [...]
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25/01/2024
License allows PharmAla to drive revenue and growth while remaining true to its “regulatory first” mission VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or [...]
Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium
25/01/2024
WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial [...]
Increase of 2023 revenue at €10.5 million
25/01/2024
Press release Ecully, January 25, 2024 – 6.00 p.m. 2023 revenue of €10.5 million In thousands of euros Unaudited data 2023 2022 % change Q1 revenue 2,399 1,342 +79% Q2 revenue 3,034 1,770 +71% Q3 revenue 2,077 2,249 -8 [...]
Hausse du Chiffres d'affaires annuel à 10,5 millions d'euros
25/01/2024
Communiqué de presse Ecully, le 25 janvier 2024 – 18h00 Chiffre d’affaires 2023 de 10,5 M€ En milliers d’euros Chiffres non audités 2023 2022 Variation 2023/2022 CA 1 er trimestre 2 399 1 342 + 79% CA 2 e trimestre 3 [...]
European Bioplastics Calls for Action to Accelerate Biopolymers Industrial Growth
25/01/2024
BRUSSELS, Belgium, Jan. 25, 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP) released its Policy Manifesto today, calling on the European Union (EU) to develop a comprehensive Biopolymers Industrial Action Plan to [...]
European Bioplastics lance un appel à l'action pour accélérer la croissance industrielle des biopolymères
25/01/2024
BRUXELLES, Belgique, 25 janv. 2024 (GLOBE NEWSWIRE) -- European Bioplastics (EUBP) a publié aujourd'hui son manifeste politique, appelant l'Union européenne (UE) à développer un plan d'action industriel complet pour les [...]
QIAGEN announces partnership with Penn State University to advance microbiome sciences
25/01/2024
Partnership aims to help shape research, education and outreach in microbiomes – the community of microorganisms within an environment // QIAGEN to provide instruments and solutions for shared research and education [...]
Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions
25/01/2024
Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million [...]
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
25/01/2024
Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors refractory to TCR [...]
Wellness Redefined: Return Healthy Launches Unique Approach to Enhancing Physical, Mental, and Emotional Resilience
25/01/2024
St. George, Utah, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Return Healthy is proud to announce the launch of its new website and revolutionary approach to holistic wellness designed to help individuals enhance their physical [...]
Castellum Announces Pricing of $2.7 Million Registered Direct Offering
25/01/2024
BETHESDA, Md., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (the “Company”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government today announced [...]
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
25/01/2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a [...]
Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.
25/01/2024
Grants, New Mexico, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) today announced the agreement to purchase assets from C2 Wellness Corporation. (“C2”), a Wyoming registered company with an [...]
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
25/01/2024
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical [...]
NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
25/01/2024
Project to benefit from Scorpius’ comprehensive services in process development, bioanalysis, and cGMP manufacturing DURHAM, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“ [...]

Pages